Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COEP Coeptis Therapeutics	$13.32 +5.2%	$10.68	$2.31 ▼ $14.70	$61.03M	-0.59	45,924 shs	41,602 shs
EDIT Editas Medicine	$2.57 -3.0%	$2.67	$0.91 ▼ $4.12	$238.29M	2.19	1.73 million shs	1.15 million shs
IMMP Prima BioMed	$1.61 -3.0%	$1.70	$1.32 ▼ $2.72	$243.67M	1.66	71,893 shs	124,420 shs
TKNO Alpha Teknova	$4.32 +0.2%	$4.72	$4.00 ▼ $10.37	$230.65M	0.32	231,980 shs	84,967 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COEP Coeptis Therapeutics	-4.95%	-5.73%	+13.54%	+37.16%	+225.28%
EDIT Editas Medicine	-0.75%	-2.93%	+2.32%	+52.74%	-27.99%
IMMP Prima BioMed	0.00%	+1.22%	-5.68%	-13.09%	-33.86%
TKNO Alpha Teknova	-3.15%	-3.79%	-10.02%	-25.17%	-7.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COEP Coeptis Therapeutics	0.657 of 5 stars	0.0	3.0	0.0	2.7	1.7	0.0
EDIT Editas Medicine	4.2154 of 5 stars	3.1	4.0	4.3	1.9	2.5	0.6
IMMP Prima BioMed	1.4885 of 5 stars	3.5	1.0	0.0	3.3	0.0	0.0
TKNO Alpha Teknova	2.394 of 5 stars	3.8	1.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
EDIT Editas Medicine	2.23	Hold	$5.10	98.44% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	334.78% Upside
TKNO Alpha Teknova	3.50	Strong Buy	$10.00	131.48% Upside

Current Analyst Ratings Breakdown

Latest COEP, IMMP, EDIT, and TKNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
7/22/2025	TKNO Alpha Teknova	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.47 per share	N/A
EDIT Editas Medicine	$32.31M	7.15	N/A	N/A	$0.21 per share	12.24
IMMP Prima BioMed	$5.14M	45.98	N/A	N/A	$1.05 per share	1.53
TKNO Alpha Teknova	$37.74M	6.13	N/A	N/A	$1.42 per share	3.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-201.73%	-108.46%	N/A
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
TKNO Alpha Teknova	-$26.75M	-$0.42	N/A	N/A	N/A	-55.24%	-26.51%	-18.40%	11/6/2025 (Estimated)

Latest COEP, IMMP, EDIT, and TKNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/7/2025	Q2 2025	TKNO Alpha Teknova	-$0.1004	-$0.07	+$0.0304	-$0.07	$9.90 million	$10.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COEP Coeptis Therapeutics	0.02	0.83	0.83
EDIT Editas Medicine	N/A	2.77	2.77
IMMP Prima BioMed	N/A	18.86	N/A
TKNO Alpha Teknova	0.17	5.87	4.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COEP Coeptis Therapeutics	13.88%
EDIT Editas Medicine	71.90%
IMMP Prima BioMed	2.32%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
COEP Coeptis Therapeutics	24.25%
EDIT Editas Medicine	2.10%
IMMP Prima BioMed	3.07%
TKNO Alpha Teknova	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COEP Coeptis Therapeutics	2	4.82 million	3.65 million	Not Optionable
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
IMMP Prima BioMed	2,021	146.79 million	142.28 million	Optionable
TKNO Alpha Teknova	240	53.51 million	46.83 million	Not Optionable

COEP, IMMP, EDIT, and TKNO Headlines

Recent News About These Companies

Alpha Teknova (NASDAQ:TKNO) Announces Earnings Results

August 11, 2025 | marketbeat.com

Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Alpha Teknova (TKNO) Q2 Revenue Jumps 7%

August 8, 2025 | aol.comA

CenterBook Partners LP Takes Position in Alpha Teknova, Inc. (NASDAQ:TKNO)

August 8, 2025 | marketbeat.com

Teknova Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025 | globenewswire.com

Pleasing Signs As A Number Of Insiders Buy Alpha Teknova Stock

July 9, 2025 | finance.yahoo.com

Martha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) Stock

July 2, 2025 | insidertrades.com

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance

June 28, 2025 | ca.finance.yahoo.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

March 11, 2025 | globenewswire.com

Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67

March 8, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COEP, IMMP, EDIT, and TKNO Company Descriptions

Coeptis Therapeutics NASDAQ:COEP

$13.32 +0.66 (+5.21%)

Closing price 04:00 PM Eastern

Extended Trading

$13.34 +0.02 (+0.15%)

As of 04:10 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Editas Medicine NASDAQ:EDIT

$2.57 -0.08 (-3.02%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 -0.02 (-0.97%)

As of 06:59 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Prima BioMed NASDAQ:IMMP

$1.61 -0.05 (-3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$1.62 +0.01 (+0.93%)

As of 06:57 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Alpha Teknova NASDAQ:TKNO

$4.32 +0.01 (+0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.32 0.00 (0.00%)

As of 07:53 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time